Suchen
60 Degrees Pharmaceuticals Inc
SXTPZur Watchlist hinzufügen
1.710USD
-0.040-2.29%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
1.75MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über 60 Degrees Pharmaceuticals Inc Unternehmen
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
60 Degrees Pharmaceuticals Inc Informationen
BörsenkürzelSXTP
Name des Unternehmens60 Degrees Pharmaceuticals Inc
IPO-datumJul 12, 2023
CEODow (Geoffrey S)
Anzahl der mitarbeiter3
WertpapierartOrdinary Share
GeschäftsjahresendeJul 12
Addresse1025 Connecticut Avenue Nw
StadtWASHINGTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl20036
Telefon12023275422
Websitehttps://60degreespharma.com/
BörsenkürzelSXTP
IPO-datumJul 12, 2023
CEODow (Geoffrey S)
Führungskräfte von 60 Degrees Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
24.13K
+30.46%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
3.95K
--
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
1.32K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
1.14K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
59.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
59.00
--
Mr. Paul Field
Mr. Paul Field
Independent Director
Independent Director
59.00
--
Mr. Patrick Gaynes
Mr. Patrick Gaynes
Investor Relations Officer
Investor Relations Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
24.13K
+30.46%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
3.95K
--
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
1.32K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
1.14K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
59.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
59.00
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von 60 Degrees Pharmaceuticals Inc?
Die fünf größten Anteilseigner von 60 Degrees Pharmaceuticals Inc sind: Dr. Geoffrey S. Dow, Ph.D.
Wie viele Institutionen halten Anteile an 60 Degrees Pharmaceuticals Inc (SXTP)?
Mit Stand vom 2026Q1 halten 27 Institutionen Anteile an 60 Degrees Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 228.38K, was 8.66% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 141573.00 gestiegen.